In NSCLC (A549, H1650, H460, H1975, PC-9, H1299, and CCD-19Lu) cells, it inhibits KRAS mutant cell lines by reducing secretory phospholipase A2-IIa (sPLA2-IIa) and NF-κB pathway activity, while inhibiting mTOR and AKT while activating AMPK [473]. Here, KRAS is linked to non-small cell lung carcinoma.